TP53 and neoplasm: However, a proportion is TP53 wild type and there is growing evidence that these latter neoplasms have an intermediate prognosis between HPV‐associated SCCs (best prognosis) and HPV‐independent TP53 mutated neoplasms (worst prognosis);82 as such, p53 immunohistochemistry or TP53 molecular testing may be useful in HPV‐independent SCCs.